Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

Diabetes. 2009 Jan;58(1):14-5. doi: 10.2337/db08-1404.

Authors

Paul M Stewart¹, Jeremy W Tomlinson

Affiliation

¹ Department of Endocrinology, University of Birmingham and University Hospital Birmingham National Health Service Foundation Trust, Birmingham, UK. p.m.stewart@bham.ac.uk

No abstract available

Publication types

Comment

MeSH terms

11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors*
11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism
Adipose Tissue / drug effects
Adipose Tissue / metabolism
Humans
Hydrocortisone / administration & dosage
Hydrocortisone / therapeutic use
Intra-Abdominal Fat / metabolism
Liver / drug effects
Liver / metabolism
Liver / pathology
Metabolic Syndrome / drug therapy*
Metabolic Syndrome / enzymology
Metabolic Syndrome / metabolism
Splanchnic Circulation / drug effects

Substances

11-beta-Hydroxysteroid Dehydrogenase Type 1
Hydrocortisone